Wegovy
Wegovy
Wegovy (pronounced weh-goh-vee) is a brand name for the drug semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of obesity.
Etymology
The name "Wegovy" is a proprietary name developed by the pharmaceutical company Novo Nordisk. The etymology of the name is not publicly disclosed.
Usage
Wegovy is used in conjunction with diet and exercise to help adults lose weight when they have certain health problems. These health problems include obesity, or overweight with related health problems such as type 2 diabetes, high blood pressure, or high cholesterol.
Mechanism of Action
Wegovy works by mimicking the effects of a hormone in the body called glucagon-like peptide-1 (GLP-1). This hormone helps to regulate blood sugar levels and slows down the emptying of the stomach, which can help to reduce feelings of hunger and increase feelings of fullness.
Side Effects
Common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.
Related Terms
External links
- Medical encyclopedia article on Wegovy
- Wikipedia's article - Wegovy
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski